Maria Vehreschild, Prof. Dr.

Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany, Germany

Disclosure(s): 3M: speaker fee; Astellas: Advisor/Consultant, speaker fee; biologische heilmittel heel gmbh: Grant/Research Support; BioNtech: Grant/Research Support; EUMEDICA: Advisor/Consultant; Farmak International Holding: Advisor/Consultant; Ferring: Advisor/Consultant, Speaker fee; Gilead Sciences: Advisor/Consultant; Immunic AG: Advisor/Consultant; MaaT: Advisor/Consultant; Merck: Advisor/Consultant, speaker fee; MSD: Advisor/Consultant, Grant/Research Support, speaker fees; Pfizer: speaker fee; Roche Molecular Systems: Grant/Research Support, speaker fees; SocraRTec R&D GmbH: Advisor/Consultant; Takeda California: Grant/Research Support

Poster(s):

• 221 - Assessment and Proposed Revision of Clinical Trial Clostridioides difficile Infection Clinical Response and Outcomes Definitions
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1142 - Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trial
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET